Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cipla with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

CIPLA vs NOVARTIS - Comparison Results

CIPLA    Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More


Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More


Current Valuations

P/E (TTM) x 40.6 328.0 12.4% View Chart
P/BV x 3.7 36.4 10.3% View Chart
Dividend Yield % 0.5 1.3 36.1%  


5-Yr Chart
Click to enlarge
High Rs663758 87.5%   
Low Rs479579 82.7%   
Sales per share (Unadj.) Rs189.0228.4 82.8%  
Earnings per share (Unadj.) Rs17.631.7 55.4%  
Cash flow per share (Unadj.) Rs34.032.8 103.9%  
Dividends per share (Unadj.) Rs3.0010.00 30.0%  
Dividend yield (eoy) %0.51.5 35.1%  
Book value per share (Unadj.) Rs176.7297.1 59.5%  
Shares outstanding (eoy) m805.1224.69 3,260.9%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.02.9 103.2%   
Avg P/E ratio x32.521.1 154.1%  
P/CF ratio (eoy) x16.820.4 82.2%  
Price / Book Value ratio x3.22.2 143.6%  
Dividend payout %17.131.5 54.1%   
Avg Mkt Cap Rs m459,72416,505 2,785.3%   
No. of employees `00023.60.7 3,534.4%   
Total wages/salary Rs m26,9011,445 1,861.3%   
Avg. sales/employee Rs Th6,446.18,441.3 76.4%   
Avg. wages/employee Rs Th1,139.42,163.6 52.7%   
Avg. net profit/employee Rs Th600.01,173.1 51.1%   
Net Sales Rs m152,1935,639 2,699.0%  
Other income Rs m3,5771,718 208.1%   
Total revenues Rs m155,7697,357 2,117.3%   
Gross profit Rs m28,264-63 -45,222.1%  
Depreciation Rs m13,22825 52,285.4%   
Interest Rs m1,14255 2,065.6%   
Profit before tax Rs m17,4701,575 1,109.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m-280-   
Extraordinary Inc (Exp) Rs m-7750-   
Tax Rs m2,501792 316.0%   
Profit after tax Rs m14,166784 1,807.8%  
Gross profit margin %18.6-1.1 -1,675.5%  
Effective tax rate %14.350.3 28.5%   
Net profit margin %9.313.9 67.0%  
Current assets Rs m108,1419,522 1,135.8%   
Current liabilities Rs m38,3223,296 1,162.7%   
Net working cap to sales %45.9110.4 41.6%  
Current ratio x2.82.9 97.7%  
Inventory Days Days9737 265.0%  
Debtors Days Days7428 261.8%  
Net fixed assets Rs m109,41146 237,850.4%   
Share capital Rs m1,610123 1,304.9%   
"Free" reserves Rs m140,6827,213 1,950.4%   
Net worth Rs m142,2927,336 1,939.5%   
Long term debt Rs m36,6210-   
Total assets Rs m228,60611,105 2,058.5%  
Interest coverage x16.329.5 55.3%   
Debt to equity ratio x0.30-  
Sales to assets ratio x0.70.5 131.1%   
Return on assets %6.77.6 88.6%  
Return on equity %10.010.7 93.2%  
Return on capital %10.022.2 44.8%  
Exports to sales %32.80-   
Imports to sales %00-   
Exports (fob) Rs m49,883NA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m51,69161 85,298.5%   
Fx outflow Rs m21,0333,630 579.4%   
Net fx Rs m30,658-3,570 -858.9%   
From Operations Rs m14,6281,610 908.6%  
From Investments Rs m-8,540687 -1,243.1%  
From Financial Activity Rs m-3,855-2,677 144.0%  
Net Cashflow Rs m2,431-380 -640.4%  

Share Holding

Indian Promoters % 16.0 0.0 -  
Foreign collaborators % 20.8 75.0 27.7%  
Indian inst/Mut Fund % 12.2 2.0 610.0%  
FIIs % 23.7 1.6 1,481.3%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 21.5 121.9%  
Shareholders   161,166 41,647 387.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster


Compare CIPLA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  

Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

CIPLA Announces Quarterly Results (1QFY19); Net Profit Up 4.7% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, CIPLA has posted a net profit of Rs 4 bn (up 4.7% YoY). Sales on the other hand came in at Rs 39 bn (up 11.7% YoY). Read on for a complete analysis of CIPLA's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY19); Net Profit Up 42.2% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, NOVARTIS has posted a net profit of Rs 100 m (up 42.2% YoY). Sales on the other hand came in at Rs 1 bn (up 20.3% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.


Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms


Sep 21, 2018 (Close)